nmm 22 4500 ICPSR02258 MiAaI m f a u cr mn mmmmuuuu 130523s2000 miu f a eng d (MiAaI)ICPSR02258 MiAaI MiAaI Drug Abuse Treatment Outcome Study (DATOS), 1991-1994 [electronic resource] [United States] United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse 2010-02-16 Ann Arbor, Mich. Inter-university Consortium for Political and Social Research [distributor] 2000 ICPSR 2258 Numeric Title from ICPSR DDI metadata of 2013-05-23. AVAILABLE. This study is freely available to the general public. Also available as downloadable files. Drug-Abuse Treatment Outcomes Study (DATOS) is a prospective study designed to determine the outcomes of adult drug abuse treatment delivered in typical, stable, community-based programs and to provide comprehensive information on continuing and new questions about the effectiveness of drug abuse treatment for adults currently available in a variety of publicly funded and private programs. The study examined the role of treatment outcomes and program type, client characteristics (including dependence, treatment history, and physical and mental health comorbidities), treatment received (e.g., length and intensity of services provided), therapeutic approaches, provision of aftercare, and research on the components of effective treatment, including factors that engage and retain clients in programs. Four types of programs were included: outpatient methadone (OPM), short-term inpatient (STI), long-term residential (LTR), and outpatient drug-free (ODF). Respondents were sampled from among adults admitted to drug abuse treatment programs in 11 representative U.S. cities during 1991-1993. Clients entering treatment completed two comprehensive intake interviews (Intake 1 and Intake 2), approximately one week apart. This information is provided in Parts 1 and 2 of the data collection. These interviews were designed to obtain baseline data on drug use and other behaviors, as well as information on background and demographic characteristics, patterns of dependence, living situation and child custody status, education and training, income and expenditures, and HIV risk behaviors, along with assessments of dependence, mental health, physical health, and social functioning. Data on criminal justice status and criminal behavior are reported in Part 5, Illegal Activities Data, and are drawn from the Intake 1 interview. Data reflecting during-treatment progress, including service delivery and client satisfaction, were collected in the one-, three-, and six-month in-treatment interviews (Parts 3, 4, and 8). The 12-Month Post-Treatment Follow-Up Interview (Part 6) replicated many of the intake questions and focused on key behaviors in the year following treatment. Part 7 includes variables for time in treatment and interview availability indicators. The 12-Month Follow-Up Urine Result data (Part 9) provide the results from urine sample tests that were given to a sample of subjects at the time of the 12-Month Follow-Up Interview. Urine specimens were tested for eight categories of drugs (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolite, methaqualone, opiates, and phencyclidine). The drugs covered in the study were alcohol, tobacco, marijuana (hashish, THC), hallucinogens or psychedelics such as LSD, mescaline, and PCP, cocaine (including crack), heroin, narcotics or opiates such as morphine, codeine, Demerol, Dilaudid, and Talwin, downers or depressants such as sedatives, barbiturates, and tranquilizers, amphetamines or other stimulants such as speed or diet pills, and other drugs. Part 10 contains data for 1393 clients who were interviewed 5 years post treatment. This part contains many of the same types of questions asked during previous interviews. Cf.: http://dx.doi.org/10.3886/ICPSR02258.v5 AIDS icpsr criminal histories icpsr demographic characteristics icpsr drug abuse icpsr drug treatment icpsr HIV icpsr mental health icpsr physical condition icpsr treatment outcome icpsr treatment programs icpsr ICPSR XVI.A. Social Indicators, United States SAMHDA VII. Drug Abuse Treatment Outcome Study (DATOS) NAHDAP I. National Addiction and HIV Data Archive Program United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse Inter-university Consortium for Political and Social Research. ICPSR (Series) 2258 Access restricted ; authentication may be required: http://dx.doi.org/10.3886/ICPSR02258.v5 nmm 22 4500 ICPSR03088 MiAaI m f a u cr mn mmmmuuuu 130523s2002 miu f a eng d (MiAaI)ICPSR03088 MiAaI MiAaI Alcohol and Drug Services Study (ADSS), 1996-1999 [electronic resource] [United States] United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies 2009-04-01 Ann Arbor, Mich. Inter-university Consortium for Political and Social Research [distributor] 2002 ICPSR 3088 Numeric Title from ICPSR DDI metadata of 2013-05-23. AVAILABLE. This study is freely available to the general public. Also available as downloadable files. The Alcohol and Drug Services Study (ADSS) was a national study of substance abuse treatment facilities and clients. The study was designed to develop estimates of the duration and costs of treatment and to describe the post-treatment status of substance abuse clients. ADSS continues and extends upon data collected in the Drug Services Research Survey, 1990: [United States] (ICPSR 3393) and the Services Research Outcome Study, 1995-1996: [United States] (ICPSR 2691) with a more complete sampling frame, an enhanced sampling design, and more detailed measures of treatment services provided, the costs of treatment, and clients in treatment. ADSS was implemented in three phases. In Phase I, a nationally representative sample of treatment facilities was surveyed to assess characteristics of treatment services and clients including treatment type, costs, program capacity, the number of clients served, waiting lists, and services provided to special populations. In Phase II, records were abstracted from a sample of clients in a subsample of Phase I facilities. This phase included four sub-components: (1) the Main Study, an analysis of abstracted records to assess the treatment process and characteristics of discharged clients, (2) the Incentive Study, which assessed the impact of varying financial payments on follow-up interview participation among non-methadone outpatient clients, (3) the In-Treatment Methadone Client study (ITMC), which assessed the treatment process of methadone maintenance, and (4) the comparison study of Early Dropout clients (EDO), which provided a proxy comparison group of records from substance abusers that went untreated. Phase III involved follow-up personal interviews with Phase II clients who could be located. This interview sought to determine post-treatment status in terms of substance use, economic condition, criminal justice involvement, and further substance abuse treatment episodes. Urine testing was conducted to validate self-reported drug use. Drugs included in the survey were alcohol, marijuana, cocaine, crack cocaine, heroin, barbiturates, benzodiazepines, amphetamines, non-prescribed use of prescription medications, abuse of over-the-counter medications, and other drugs. ADSS also included a cost study, which involved obtaining additional financial information from the Phase II facilities. A computerized desktop audit was used in the cost study to conduct consistency and accuracy checks on selected questionnaire data from Phases I and II. Variables were subsequently updated to represent the most accurate data available. Additional analysis variables were then created using combinations of the revised Phase I and II data. Cf.: http://dx.doi.org/10.3886/ICPSR03088.v5 AIDS icpsr alcohol abuse icpsr drug abuse icpsr drug treatment icpsr health care services icpsr HIV icpsr intervention icpsr methadone maintenance icpsr substance abuse icpsr substance abuse treatment icpsr treatment compliance icpsr treatment outcome icpsr treatment programs icpsr ICPSR XVI.A. Social Indicators, United States NAHDAP I. National Addiction and HIV Data Archive Program SAMHDA XV. Alcohol and Drug Services Study United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies Inter-university Consortium for Political and Social Research. ICPSR (Series) 3088 Access restricted ; authentication may be required: http://dx.doi.org/10.3886/ICPSR03088.v5 nmm 22 4500 ICPSR03404 MiAaI m f a u cr mn mmmmuuuu 130523s2004 miu f a eng d (MiAaI)ICPSR03404 MiAaI MiAaI Drug Abuse Treatment Outcome Study--Adolescent (DATOS-A), 1993-1995 [electronic resource] [United States] United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse 2008-10-07 Ann Arbor, Mich. Inter-university Consortium for Political and Social Research [distributor] 2004 ICPSR 3404 Numeric Title from ICPSR DDI metadata of 2013-05-23. AVAILABLE. This study is freely available to the general public. Also available as downloadable files. Drug Abuse Treatment Outcome Study - Adolescent (DATOS-A) was a multisite, prospective, community-based, longitudinal study of adolescents entering treatment. It was designed to evaluate the effectiveness of adolescent drug treatment by investigating the characteristics of the adolescent population, the structure and process of drug abuse treatment in adolescent programs, and the relationship of these factors with outcomes. Three major types or modalities of programs included in the study were chemical dependency or short-term inpatient (STI), therapeutic community or residential (RES), and outpatient drug-free (ODF). The adolescent battery of instruments included intake, intreatment, and follow-up questionnaires based largely on the DATOS adult study DRUG ABUSE TREATMENT OUTCOME STUDY (DATOS), 1991-1994: [UNITED STATES] (ICPSR 2258) instrument format, with considerable tailoring to the adolescent population. Clients entering treatment completed two comprehensive intake interviews (Intake 1 and Intake 2), approximately one week apart. This information is provided in Parts 1 and 2 of the data collection. These interviews were designed to obtain baseline data on drug use and other behaviors, such as illegal involvement, as well as information on background and demographic characteristics, education and training, mental health status, employment, income and expenditures, drug and alcohol dependence, health, religiosity and self-concept, and motivation and readiness for treatment. The one-, three-, and six-month intreatment interviews (Parts 3, 4, and 7) included items on treatment access, intreatment experience, and psychological functioning, as well as questions replicated from some of the domains in the Intake 1 and 2 questionnaires. The 12-month post-treatment follow-up interview (Part 5) included questions replicated from the previous interviews, and also included post-treatment status. Part 6 includes variables for time in treatment and interview availability indicators. The Measures Data (Part 8) were generated by using the Diagnostic and Statistical Manual of Mental Disorders (Rev. 3rd ed., DSM-III-R) (American Psychiatric Association, 1987). The variables in Part 8 give either the DSM-III-R level of dependence to a drug category or they describe whether the subject meets the DSM-III-R standard for a particular disorder. The 12-Month Follow-up Urine Result data (Part 9) provide the results from urine sample tests that were given to a sample of subjects at the time of the 12-Month Follow-up Interview. The urine test was used to ascertain the nature and extent of bias in the self-reports of the respondents. Urine specimens were tested for eight categories of drugs (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolite, methaqualone, opiates, and phencyclidine). The drugs covered in the study were alcohol, tobacco, marijuana (hashish, THC), cocaine (including crack), heroin, narcotics or opiates such as morphine, codeine, Demerol, Dilaudid, and Talwin, illegal methadone, sedatives and tranquilizers such as barbiturates and depressants, amphetamines or other stimulants such as speed or diet pills, methamphetamines, LSD, PCP, and other hallucinogens or psychedelics, and inhalants such as glue, gasoline, paint thinner, and aerosol sprays. The study also included drug of choice, frequency, and route of administration. Cf.: http://dx.doi.org/10.3886/ICPSR03404.v3 adolescents icpsr AIDS icpsr alcohol abuse icpsr drug abuse icpsr drug treatment icpsr drug use icpsr education icpsr employment icpsr health icpsr HIV icpsr mental health icpsr sexual behavior icpsr substance abuse treatment icpsr tobacco use icpsr treatment outcome icpsr treatment programs icpsr ICPSR XVI.A. Social Indicators, United States SAMHDA XXII. Drug Abuse Treatment Outcome Study - Adolescent (DATOS-A) NAHDAP I. National Addiction and HIV Data Archive Program United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse Inter-university Consortium for Political and Social Research. ICPSR (Series) 3404 Access restricted ; authentication may be required: http://dx.doi.org/10.3886/ICPSR03404.v3